Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase kinase (MAP2K) is a key component of the three-tiered MAP kinase signaling cascade, which consists of MAP kinase (MAPK), MAP kinase kinase (MAP2K), and MAP kinase kinase kinase (MAP3K)[1][5]. MAP2K is activated through phosphorylation by upstream MAP3Ks in response to various stimuli including mitogens, cytokines, and environmental stresses[1]. Once activated, MAP2K phosphorylates and activates specific downstream MAP kinases, which then regulate various cellular processes including proliferation, differentiation, and apoptosis[5]. The MAP2K family includes at least seven members (MKK1-7), each with specific roles in activating different MAP kinase groups[5]. MAP2Ks are dual-specificity kinases, capable of phosphorylating both threonine and tyrosine residues on their MAP kinase substrates[6][9]. The specificity of MAP2Ks for their substrates ensures proper signal transduction in response to different stimuli. Structurally, MAP2K contains a kinase domain and a PB1 domain at the N-terminus that is involved in protein-protein interactions and the formation of macromolecular signaling complexes[9]. The structure of MAP2K (specifically MEK6) reveals an autoinhibited elongated ellipsoidal dimer in its inactive state[6]. Due to their central role in cellular signaling pathways, particularly those involved in cell proliferation and survival, MAP2Ks have emerged as important therapeutic targets, especially in cancer treatment[9]. Mutations or dysregulation of MAP2Ks have been implicated in various diseases, including different types of cancer, with MAP2K4 mutations being particularly prevalent in breast cancer[9].
MAP2K functions by phosphorylating and activating specific MAP kinases - Different MAP2K family members activate different MAP kinase groups: - MKK1 and MKK2 activate ERK MAP kinases - MKK3, MKK4, and MKK6 activate p38 MAP kinases - MKK4 and MKK7 activate JNK MAP kinases[5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase kinase (MAP2K).